NCT00137397View on ClinicalTrials.gov

A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2004

Study Completion Date

August 31, 2006

Conditions

Urinary Incontinence

Interventions

DRUG

Tolterodine ER

DRUG

Placebo

Trial Locations (11)

BB2 3HH

Pfizer Investigational Site, Blackburn

HA1 3UJ

Pfizer Investigational Site, Harrow

OX3 9DU

Pfizer Investigational Site, Oxford

EH54 6PP

Pfizer Investigational Site, Livingston

RG24 9NA

Pfizer Investigational Site, Basingstoke

B15 2TG

Pfizer Investigational Site, Birmingham

PE18 8NT

Pfizer Investigational Site, Cambs

SE5 9RS

Pfizer Investigational Site, London

W2 2YP

Pfizer Investigational Site, London

NN1 5BD

Pfizer Investigational Site, Northampton

Unknown

Pfizer Investigational Site, Pl6 8Dh

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00137397 - A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder | Biotech Hunter | Biotech Hunter